Cyanotech (CYAN) Peer Comparison
$0.53
$0.02
(3.92%)
As on 03-Sep-2026 16:00EDT
Market cap
$4 Mln
Revenue (TTM)
$27 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Edit
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
4 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
27 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
-0.07 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
-0.25 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-0.87 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 264.84 | -- | -- |
Price-To-Book |
0.42 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
26.59 | 502.08 | 761.41 | 4,715.00 | 638.50 |
|
Cost of Revenue
|
17.91 | 28.27 | 12.98 | 2,665.00 | 47.48 |
|
Gross Profit
|
8.67 | 473.81 | 748.43 | 2,050.00 | 591.02 |
|
Operating Expenses
|
9.25 | 1,042.89 | 703.63 | 1,798.00 | 760.25 |
|
Operating Profit (EBIT)
|
-0.57 | -569.09 | 44.80 | 252.00 | -169.24 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-1.28 | -734.99 | 66.46 | -224.00 | -183.70 |
|
Provision for Tax
|
0.01 | 0.56 | -33.19 | 8.00 | -0.53 |
|
Profit after Tax (Net Income)
|
-1.28 | -729.31 | 99.65 | -232.00 | -183.17 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
7.66 | -2,076.58 | 647.81 | 6,547.00 | 88.30 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
3.76 | 2,724.64 | 22.76 | 5,214.00 | 222.67 |
|
Current Liabilities
|
10.70 | 287.97 | 166.09 | 1,597.00 | 378.84 |
|
Total Liabilities
|
22.13 | 936.03 | 836.65 | 13,358.00 | 689.81 |
Assets ($ Mln)
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
11.25 | 41.59 | 351.19 | 9,900.00 | 100.82 |
|
Current Assets
|
10.87 | 753.68 | 485.46 | 3,458.00 | 588.99 |
|
Total Assets
|
22.13 | 936.03 | 836.65 | 13,358.00 | 689.81 |
|
Total Debt*
|
11.60 | 2,728.72 | 6.11 | 4,017.00 | 241.30 |
|
Net Current Assets
|
0.30 | 509.78 | 319.38 | 1,861.00 | 210.15 |
Cashflow ($ Mln)
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
0.23 | -445.91 | 142.00 | 560.00 | -93.41 |
|
Cash Flow from Investing Activities
|
-0.14 | -24.49 | 69.76 | -279.00 | -0.48 |
|
Cash from Financing Activities
|
0.46 | 359.29 | -220.37 | -275.00 | 101.47 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-6.46 | -159.44 | 14.87 | -2.21 | -63.21 |
|
ROE (%)
|
-15.50 | 41.15 | 15.01 | -3.67 | -252.11 |
|
ROA (%)
|
-5.62 | -78.62 | 11.88 | -1.79 | -29.11 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-4.82 | -145.26 | 13.09 | -4.92 | -28.69 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.10 | 1.26 | 0.13 | 0.06 | 0.66 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
59.98 | -36.12 | -28.68 | -168.64 | 36.22 |
|
EPS Growth (%)
|
0.61 | -0.31 | -0.30 | -1.68 | 0.39 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.70 | -20.69 | 41.86 | -48.47 | -50.48 |
|
Price / Book Value
|
0.28 | -7.27 | 6.44 | 1.72 | 104.73 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
9.89 | -25.60 | 55.67 | 21.77 | -54.53 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.51 | -1.31 | 0.01 | 0.61 | 2.73 |
|
Short term debt to equity ratio
|
1.02 | -0.01 | 0.00 | 0.01 | 0.83 |
|
Current Ratio
|
1.02 | 2.62 | 2.92 | 2.17 | 1.55 |
|
Quick Ratio
|
0.42 | 2.52 | 2.85 | 1.08 | 1.48 |
|
Interest Coverage
|
-0.82 | -12.84 | -- | -0.02 | -27.02 |
Operating Efficiency Ratios
| Cyanotech (CYAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.21 | 27.77 | 7.85 | 19.94 | 35.16 |
|
Asset Turnover
|
1.17 | 0.54 | 0.91 | 0.36 | 1.01 |
|
Receivable days
|
35.72 | 52.44 | 28.27 | 70.73 | 104.82 |
|
Inventory Days
|
144.00 | 172.81 | 355.76 | 226.89 | 167.98 |
|
Payable days
|
39.96 | 296.14 | 785.55 | 45.50 | 529.03 |
|
Cash Conversion Cycle
|
139.75 | -70.89 | -401.52 | 252.12 | -256.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
